Gene Therapy Clinical Trials
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Eligibility
Inclusion Criteria:
1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the
duration of the study
3. Aged at least 18 years old at time of consent
4. Diagnosed with AML, in complete remission
1. Complete remission (CR) definition per local institutional criteria
2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion
3. MRD positivity is not an exclusion criterion
5. Undergoing alloHCT
6. Has specimen from time of AML diagnosis available
Exclusion Criteria:
1. Diagnosis of acute promyelocytic leukemia
2. Prior alloHCT
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Audrey Xu
650-725-1647
I'm interested